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Abstract 
Objective: We sought to examine highly sexually active gay and bisexual men’s accuracy in 
predicting their sexual behavior for the purposes of informing future research on intermittent, 
event-driven HIV Pre-Exposure Prophylaxis (PrEP). 
Design:  For 30 days, 92 HIV-negative men completed a daily survey about their sexual 
behavior (n = 1,688 days of data) and indicated their likelihood of having anal sex with a casual 
male partner the following day. 
Method: We utilized multilevel modeling to analyze the association between self-reported 
likelihood of and subsequent engagement in anal sex. 
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Results: We found a linear association between men’s reported likelihood of anal sex with 
casual partners and the actual probability of engaging in sex, though men overestimated the 
likelihood of sex. Overall, we found that men were better at predicting when they would not have 
sex than when they would, particularly if any likelihood value greater than 0% was treated as 
indicative that sex might occur. We found no evidence that men’s accuracy of prediction was 
affected by whether it was a weekend or whether they were using substances, though both did 
increase the probability of sex. 
Discussion: These results suggested that, were men taking event-driven intermittent PrEP, 14% 
of doses could have been safely skipped with a minimal rate of false negatives using guidelines 
of taking a dose unless there was no chance (i. ., 0% likelihood) of sex on the following day. 
This would result in a savings of over $1,300 per year in medication costs per participant.  
Keywords:  Gay and bisexual men; HIV/AIDS; intermittent PrEP; event-driven PrEP; predicting 
sexual behavior  
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Introduction 
Gay, bisexual, and other men who have sex with men (GBMSM) continue to 
disproportionately bear the burden of the epidemic.1,2 There is an urgent need for effective 
biomedical and behavioral strategies to reduce incidence in this population. In 2012, the FDA 
approved the use of once-daily Truvada (Emtricitabine/Tenofovir) for use among HIV-negative 
individuals as HIV Pre-Exposure Prophalyxis (PrEP), and the CDC subsequently recommended 
combined once-daily Truvada to be coupled with traditional HIV prevention/education (e.g., 
condom use).3-5 PrEP is, at present, one of the most promising biomedical prevention tools for 
GBMSM in the US. 
Daily dosing may not be necessary for all PrEP candidates. First, most individuals are not 
exposed to HIV on a daily basis and Truvada has a relatively long half-life in plasma and 
peripheral blood mononuclear cells (≥60 and 39 hours).6,7 This suggests less frequent dosing 
might maintain sufficient levels to prevent infection in the event of an exposure. In fact, results 
from the iPrEx Open Label Extension (OLE) study—a PrEP demonstration project—found no 
new HIV infections among those who took Truvada at least 4 days per week.8 S cond, daily 
dosing, compared with less frequent dosing, might be considered burdensome in several ways, 
including the physical act of swallowing the pill, the cognitive burden of remembering daily, the 
potential for increased treatment side effects or toxicity, and the financial costs.9-11  
As data from animal models regarding the efficacy of intermittent PrEP are 
promising,12,13 two intermittent PrEP dosing strategies are being studied in humans as 
alternatives to daily dosing—time-driven and event-driven dosing. In the HPTN 067 (ADAPT) 
study, daily dosing is being compared to both time-driven and event-driven dosing. The time-
driven arm involves one dose of Truvada taken twice weekly regardless of sexual activity and an 
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additional post-exposure dose after any sexual act; the event-driven arm in the ADAPT trial 
involves one dose 24-48 hours before sexual intercourse and a second within two hours of 
intercourse.14 In the IPERGAY trial,15 a different form of event-driven dosing is utilized—two 
doses of Truvada are taken 2-24 hours before any anticipated sexual intercourse and, if sexual 
behavior occurs, two doses are taken with the first occurring 24 hours and a second 48 hours 
after sexual activity. On October 29, 2014, the IPERGAY study announced that preliminary 
results examined by their Data Safety Monitoring Board indicated a significant difference in HIV 
incidence between those receiving event-driven dosing and placebo, and closed the placebo 
arm.16 This suggests that event-based dosing may soon be among the recommended PrEP 
strategies, particularly since a recent study of potential PrEP users in Kenya found no differences 
in preferences for daily versus event-driven regimens.11 Although the full extent of the efficacy 
of intermittent dosing will not be known until these trials are completed, effectiveness of event-
driven dosing will likely depend on the ability of individuals to predict in advance when sex will 
occur.   
There are important caveats to intermittent PrEP dosing strategies. Individuals who 
typically experience three or more exposures in a given week might be better served by daily 
PrEP.17 Similarly, event-driven PrEP requires individuals to dose shortly following the time that 
exposure occurs. In a study of GBMSM and female sex workers, adherence rates for daily dosing 
(83%) were significantly higher than for intermittent dosing (55%) and dosing after sex (26%),9 
and similar findings emerged in a study of HIV serodiscordant couples in Uganda.18  However, 
preliminary results from the IPERGAY trial suggest high adherence to intermittent dosing, with 
participants on average taking 15 doses per month.19 
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There is little research to suggest whether GBMSM can accurately predict when sexual 
events will occur. In a study of 1,013 U.S. men online, Volk et al.17 reported that 50.4% of 
GBMSM had no advanced planning prior to their last sexual encounter, and 8.2% reported 
planning only minutes in advance. The remaining men reported planning hours (22.4%), 1–3 
days (10.7%), or more than 3 days in advance (8.4%). Similarly, in a study of 823 GBMSM in 
Bangkok, Thailand, men reported that more than two-thirds of their sex events from the previous 
week were planned, though how far in advance men planned the events was not reported.20 B th 
studies suggested some men were able to plan sexual events in advance. However, these analyses 
relied upon retrospective recall data potentially overestimating the extent to which individuals 
were able to predict their own behavior.  
Addressing these limitations, the present study was designed to use prospective (i.e., 
daily diary) analyses to examine the accuracy of GBMSM in predicting the next day’s sexual 
behavior for the purposes of informing future research on alternative PrEP dosing schedules. Our 
sample included GBMSM who reported high numbers of sexual partners—a group explicitly 
targeted in CDC guidelines for PrEP utilization.21 Our a priori assumption is that the most 
important classification statistic to minimize is false negatives—where the individual believes 
they will not have sex the next day and does not take a PrEP dose, but ultimately has sex on the 
next day. A secondary classification priority was avoiding medication waste by taking it 
unnecessarily the day before sex does not occur (i.e., precision).   
Method 
Analyses were conducted on data from The Pillow Talk Project, a study of highly 
sexually active (i.e., ≥ 9 male partners in 90 days) gay and bisexual men (GBM) in New York 
City.22,23 The analyses were limited to the 208 men confirmed to be HIV-negative with a rapid 
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HIV test. One man did not complete any of the daily diaries and was excluded from analyses. 
We did not implement the question that is the main focus of these analyses until July, 2012. As 
such, 115 men never received this question. This resulted in a sample of 92 men with an average 
completion rate of 78.1% (M = 23.4 days) and median rate of 86.7% (Mdn = 26.0 days). 
Analyses involved the creation of a time-lagged variable and as such, contiguous reporting was 
required (see “daily diary measures”). In all, 341 days’ worth of data were unmatched, resulting 
in a final analytic dataset of 1,688 days across 92 HIV-negative, highly sexually active GBM. 
Participants and Procedures 
Potential participants completed a phone-based screening to assess eligibility, which was 
defined as: 1) at least 18 years of age; 2) biologically male and self-identified as male; 3) nine or 
more male sexual partners in the prior 90 days;24-28 4) self-identification as gay, bisexual, or 
some other non-heterosexual identity; and 5) daily access to the Internet. Participants who met 
preliminary eligibility were emailed a link to an Internet-based computer-assisted self-interview 
(CASI), which included informed consent procedures. Men completed this one-hour survey at 
home followed by an in-person baseline appointment. Final eligibility and enrollment was 
confirmed during the in-person appointment, with sexual partner criteria confirmed using a 
timeline follow-back (TLFB) interview. Following the baseline, participants received a unique 
link to complete their diaries each night for 30 days. All procedures were approved by the 
Institutional Review Board of the City University of New York.  
Measures 
Online CASI measures. Participants were asked to report demographic characteristics, 
including sexual identity, age, race/ethnicity, education, and relationship status. 
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Daily diary measures. The diary measure was based on previous studies conducted with 
GBM.29-31 Each day, participants reported on their substance use and we calculated one indicator 
(1 = yes, 0 = no) of whether the participant had consumed five or more alcoholic drinks (i.e., 
heavy drinking) and a second for whether they had used cocaine, crack, crystal meth, ecstasy, 
heroin, ketamine, or GHB (i.e., club drugs). Following those sections, participants were asked 
whether they had engaged in any sexual activity with another person and, if so, were asked a 
series of questions for each partner they reported for that day. For the purposes of these analyses, 
we recoded all partner-level data into a single day-level indicator of whether or not (1 = yes, 0 = 
no) the participant had engaged in any anal sex with a casual male partner. At the end of the 
survey, participants were asked, “How likely is it that you will have anal sex with a casual male 
partner tomorrow?” and were given a visual analog-style sliding scale ranging from 0 (absolutely 
sure I will not) to 100 (absolutely sure I will). This variable was time-lagged such that it was 
matched with the sexual behavior report on the next day to estimate their accuracy in prediction. 
The variable was also centered at 50 and divided by 10 such that a one-unit increase 
corresponded to an increase of 10% in self-reported likelihood. 
Analytic Plan 
All models were conducted using multilevel logistic regression accounting for a first-
order autoregressive (i.e., AR1) structure in the repeated responses and a random intercept with 
an unstructured covariance matrix using SAS version 9.2’s GLIMMIX procedure. To inform 
recommendations regarding cutoff points in likelihood ratings and their utility for when to take a 
PrEP dose prior to a sexual occasion, we estimated two theoretically relevant classification 
statistics across the range of self-reported likelihood of sex: the false negative rate (i.e., [below 
the cutoff but had sex]/[all those who had sex]; on what percentage of days when a pill would 
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have been needed would the participant not have taken one at the specified cutoff?) and 
precision (i.e., [at or above the cutoff and had sex]/[all those at or above the cutoff]; on what 
percentage of days when a pill would have been taken was the dose actually needed?). 
Results 
As shown in Table 1, the sample was diverse with regards to race/ethnicity, employment 
status, and educational achievement, while a majority was gay-identified and single. 
Additionally, nearly two-thirds of the sample engaged in sexual activity on three or more days 
per week. Figure 1 presents a histogram of the likelihood responses, with those greater than 0% 
collapsed into deciles. The most commonly reported single point on the likelihood scale was 0%, 
with an average likelihood of 26.3% (SD = 26.4%; Mdn = 19.0%; IQR = 4-41%).  
[Table 1 Here] 
[Figure 1 Here] 
We tested for linearity of the association between self-reported likelihood and behavior 
by creating 11 dichotomous indicators of each decile on the likelihood variable (e.g., 0%, 1-10%, 
91-100%) and examining their association with behavior. As can be seen in Figure 1, the 
association was primarily linear. We also explored this issue using both first-order and quadratic 
terms predicting the behavioral outcome and found no evidence of a significant quadratic effect. 
As such, further analyses were conducted examining a linear association between likelihood 
reports and behavior. In a model with only the continuous likelihood rating, the odds of sex on 
an average day with a 50% likelihood rating was 0.30 (probability = 0.23) and this increased by 
36% (OR = 1.36) for every 10% increase in self-reported likelihood. We found that the effect of 
time (i.e., the day of diary completion) did not have an influence on the outcome, but that 
weekend days (i.e., Friday, Saturday, Sunday) versus weekdays were associated with increased 
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odds of anal sex with casual partners (OR = 1.31, 95%CI [1.00, 1.72]). We found no evidence of 
an interaction between likelihood ratings and whether or not it was a weekend day. That is, 
though men tended to be more sexually active on the weekends, this neither improved nor 
worsened their accuracy of prediction. As a result of its significant main effect, we subsequently 
adjusted all models for whether or not the day on which the behavior was measured on a 
weekend day. 
In the next series of multilevel models, we separately tested level 1 (i.e., daily) substance 
use variables for main effects on the outcome as well as interaction effects with the likelihood 
rating to examine whether certain contextual effects might influence the accuracy of participants’ 
reports. Both heavy drinking (AOR=1.63, 95%CI[1.06, 2.49]) and drug use (AOR=2.64, 
95%CI[1.21, 5.75]) on a given day had significant main effects on whether or not participants 
engaged in casual anal sex, but neither significantly interacted with likelihood ratings to decrease 
participants’ accuracy of prediction (AOR=0.97, 95%CI [0.84, 1.13]; AOR=0.83, 95%CI [0.66, 
1.05], respectively). 
[Figure 2 Here] 
Figure 2 provides estimates of classification statistics across the observed range of self-
reported likelihoods of having sex on the next day. As shown, the rate of false negatives 
increased sharply as participants increased their ratings of sex likelihood. If a threshold even as 
low as 10% sex likelihood was set for taking a PrEP dose, then a missed dose would have 
occurred on 12.6% of days when an individual would have needed a dose prior to sex. At this 
same threshold of 10% likelihood, only 20.5% of the doses that would be taken would actually 
have been subsequently needed (i.e., 79.5% of the time they would be taking a dose that was 
unnecessary because sex ultimately did not occur the next day). Using anything greater than 0% 
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likelihood of having sex as the cutoff, the rate of false negatives was 3.8% and precision was 
similar to values at 10% likelihood (17.3% versus 20.5%).  Ratings of 0% likelihood occurred on 
14.0% of days (i.e., ratings greater than 0% likelihood occurred on 86% of days). Overall, there 
were no levels of self-reported likelihood where participants had good precision in their 
predictions; even at a cutoff of 100%, doses would be unnecessary 41.4% of the time that they 
were taken.  
Discussion 
Based on our results, there appear to be two approaches that could be used to inform 
event-driven intermittent PrEP use among GBMSM where a dose needs to be taken a day prior 
to sex. The first strategy would counsel individuals to “Take a dose today unless you are n t 
going to have sex tomorrow.”  Under this strategy, classification statistics suggest a 
recommended a 1% or greater chance of sex the next day be used; in other words, individuals 
would be instructed to only skip a daily dose when they were certain there would be no chance 
of having sex the next day. In this sample, the 0% likelihood value produced a rate of 3.8% false 
negatives (i.e., cases where sex was not predicted but did occur the next day). Although a 0% 
chance of sex may seem like a very stringent criterion, it has a number of beneficial properties 
beyond the important characteristic of minimizing false negatives. This value was the most 
common prediction point—even in this sample of highly sexually active men—with participants 
reporting 0% likelihood an average of 4.2 days per month.  In our sample, this means that 14% 
of doses could have been skipped without increasing risk for transmission in the proceeding 24 
hours. At an estimated cost of $25.86 per dose,32 this would save an average of $1,321.45 per 
year in medication costs per participant (i.e., more than 1.5 months’ worth of medication). Given 
known innumeracy issues in individuals’ ability to interpret probabilities,33 and the fact that men 
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were better at predicting when they would nothave sex than when they would, another beneficial 
feature of this cut point is that it is easy to apply (i.e., “only skip a dose if you are certain there is 
no chance you will have sex tomorrow”) versus an intermediate value.  Perhaps most 
importantly, the consequence of making a wrong decision under this strategy are rather benign 
(i.e., an unnecessary dose is taken). 
A second potential counseling strategy for those on event-driven dosing would be to 
focus on sexual forecasting, working with GBMSM to identify which days of the week they are 
likely to have sex and instruct them to “Take a dose if there is any chance you are going to have 
sex the next day.” This is similar to the counseling approach being used in HPTN 067 (ADAPT) 
and will be effective when users can have high precision in their predictions at the same time as 
avoiding false negatives. However, our study suggests that, among highly sexually active GBM, 
this approach would not be effective because classification statistics indicate the men had low 
levels of precision in predicting their sexual behavior across the full range of likelihood ratings 
(15.5% - 58.6%). Even at a reported 100% likelihood of sex occurring the next day, precision 
was only 58.6% and the false negative rate was unacceptably high at this likelihood level (i.e., 
94%). Most importantly, the consequences of making a wrong decision under this strategy are 
high (i.e., a necessary dose would not be taken, therefore increasing risk of infection).   
[Table 2 Here] 
Importantly, our findings also suggest that the fixed dosing schedule may be the most 
appropriate for men who have at least one sexual event per week. Table 2 contains a hypothetical 
week for the ADAPT and IPERGAY trial dosing schedules based on sexual behavior. As can be 
seen, the fixed dosing schedule in ADAPT would lead to a greater number of doses than the 
other two schedules only during weeks when no sexual activity is anticipated or occurs (within 
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the table, perfect correspondence between prediction and behavior is assumed). In contrast, the 
IPERGAY event-driven dosing schedule may lead to as many as eight doses in a week with only 
two anticipated and actual sex events, which is more than the number of doses taken with daily 
PrEP. The event-driven dosing in ADAPT and IPERGAY is contingent upon successfully 
predicting one’s sexual behavior such that a pre-coital dose can be taken—in ADAPT’s event-
driven dosing, a single dose is taken between 24-48 hours prior to sexual activity while 
IPERGAY’s event-driven schedule calls for two doses taken 2-24 hours prior to sexual activity. 
Table 2 assumes perfect correspondence between anticipated and actual sexual behavior, which 
the current study demonstrated is rarely the case. Rather, our findings demonstrate that, in 
general, attempting to make a prediction approximately 24 hours in advance led to very 
imprecise estimates and would ultimately lead to pre-coital doses being taken on all but 
approximately one day per week, on average. In contrast to this, the IPERGAY schedule, while 
requiring a greater number of pre-coital doses (i.e., 2 pills rather than one), could ultimately 
result in fewer doses per week if participants are more accurate at predicting sex within shorter 
intervals of time (i.e., the 2-24 hours recommended in the IPERGAY schedule). Although this is 
not depicted within the table due to the complexity, this may result in fewer pre-coital doses 
being taken due to greater accuracy in predicting sex at shorter intervals, though it would result 
in more doses being taken after actual engagement in sexual behavior. 
Overall, it is impossible to say with the current data which dosing schedule will lead to 
the most adaptive plan due to the fact that all estimates were requested on the day prior rather 
than on the day of a sexual event as would be possible within the IPERGAY schedule. More 
information is required about the potential increases in accuracy at these shorter intervals to 
determine how many pills could ultimately be skipped safely and what the resultant cost savings 
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would be. These data are not able to shed light on the potential efficacy of any of these dosing 
schedules. However, the data do suggest that men would meet the level of 4 doses per week with 
only one sexual event per week in IPERGAY and with two sexual events in the fixed dosing 
schedule of the ADAPT trial, though they may not receive a minimum of four doses at two 
sexual events per week using the event-driven dosing in ADAPT, depending on the distance 
between sexual events as can be seen in the final two hypothetical weeks in Table 2. Given that 
recent research suggests that four doses may be optimal for preventing infection,8 and the recent 
discontinuation of the placebo arm in the IPERGAY trial suggesting efficacy of event-driven 
dosing,16 our data suggest that men who have one to two sexual events per week may be best 
advised by the IPERGAY event-driven dosing schedule given both its flexibility with pre-coital 
prediction intervals and the number of doses that would be achieved. However, for men for 
whom sexual behavior is more regular, the IPERGAY schedule may lead to more doses than 
would be required by daily PrEP and these men may be better suited to utilize the fixed ADAPT 
event-driven dosing schedule combined with the suggestion from these data that they take a pre-
coital dose unless they believe there is no chance of sexual behavior on the following day. These 
results may lead to both the optimal dosing levels and cost savings.
In addition to informing strategies for how to counsel event-driven PrEP users on how to 
predict sex and adjust their dosing, this study also provided novel information on how well men 
could predict their future sexual behavior. In this sample of highly sexually active GBM, 
participants consistently overestimated the likelihood that sex would occur across the range of 
likelihoods. For example, when men predicted between 71-80% likelihood of having sex, the 
actual probability was 45.7%. In the absence of data on such predictions among GBM who are 
less sexually active, it is unknown if this represents a general affirmative bias among GBM (or 
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men in general), or whether the characteristics of this study population may moderate prediction 
tendency. For example, highly sexually active men may be more likely to predict sex will occur 
due to their higher overall frequency of sex. Other important findings included the lack of effect 
moderation due to weekend versus week day or substance use during sex; although both 
increased the probability of having sex, they did not decrease men’s accuracy of prediction. This 
suggests that GBM may have accounted for these variables in their predictions of the likelihood 
of sex occurring.   
 This study is not without limitations. First, this was a sample of highly sexually active 
GBM in NYC, and therefore results may not generalize across the distribution of sexual activity 
levels. At the same time, the population is one of the primary targets for PrEP utilization,21 nd 
therefore our findings have particular relevance. Second, it is important to note that the data 
came from an observational diary study and participants had no incentive to change their sexual 
behavior based on their predictions. In the case of event-driven PrEP, users may have an 
incentive to change their behavior depending on if they predicted sex and therefore took a PrEP 
dose on the prior day. These changes could include avoiding sex when a dose was not taken in 
advance, which would decrease false negatives, increasing condom use when a dose was not 
taken the prior day, or being more inclined to engage in sex on days after a dose was taken, 
which would increase the precision of their predictions. To the extent that this strategy of event-
driven intermittent PrEP dosing is effective at preventing HIV infection, then such an increase 
would be inconsequential. Lack of effectiveness, however, would produce negative 
consequences akin to risk compensation.34 Finally, the sample size was limited to fewer than 100 
men, and thus we lacked power to examine many potential individual-level moderators of 
prediction accuracy, including level of risk. Moreover, the likelihood question, and thus the 
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outcome examined, focused only on sex with casual partners. Future studies are needed that 
more carefully examine which individual characteristics make men better or worse at accurately 
predicting their behavior and incorporate the role of relationships within the analyses. 
In conclusion, our unique daily diary data allowed for estimation of how well highly 
sexually active GBM can predict when sex will occur on the next day. Such data have been 
missing from the discussion of event-driven intermittent PrEP utilization. On an a priori basis 
we concluded that the most important classification statistic to minimize was false negatives, as 
they would serve to increase risk for infection because a needed dose it not taken. Our diary data 
indicated there were very few false negatives when participants indicated there was 0% chance 
of sex occurring the next day, and therefore suggest that the most effective approach for this 
population is to advise that a dose should be taken every day, unless the user is certain that sex 
will not occur the next day. This recommendation is essentially equivalent to daily PrEP minus 
days in which sex is not going to occur the next day.  In the diary data there were many such 
days, and therefore this approach could produce considerable cost savings, which is critical 
because existing analyses indicate cost-effective implementation of daily PrEP would be 
challenging in the U.S.32,35,36. It is also expected that less frequent dosing would decrease side-
effects related to drug exposure,21 which could impact adherence. Given these benefits of event-
driven PrEP, future trials of this event-driven intermittent usage strategy are likely to be 
conducted if the results of current trials support efficacy. If our results are replicated in further 
studies, future event-driven PrEP trials may be able to increase efficacy by shifting their 
counseling strategy to one of “take a dose unless you are certain there is no chance sex will occur 
tomorrow.” Such strategies may lead to even greater cost savings among men with less frequent 
sexual activity.
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[See PowerPoint Slide 1] 
Figure 1. This figure displays a histogram of the frequency of self-reported likelihood within the 
bar chart while also displaying the model-implied probability of anal sex with a casual partner 
based on 11 percentiles of self-reported likelihood as a solid black line (the 95% confidence 
interval for the predicted values is displayed as a gray shadow around the solid line). The dotted 
black line serves as a referent for what a line of perfect correspondence between reported 
likelihood and actual behavior. As can be seen, participants tended towards lower predictions 
regarding the likelihood of sex on the next day, and the association between self-reported 
likelihood and subsequent engagement in sex was relatively linear. 
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[See PowerPoint Slide 2]   
Figure 2. Classification statistics for predicting anal sex with a casual male partner across the 
range of self-reported likelihood of having sex the next day.  The false negative rate represents 
the proportion of false negatives (i.e., those who had sex but were not predicted to based on their 
likelihood score) over all actual positives (i.e., people who had sex).  Precision represents the 
rate of true positives (i.e., people who were predicted to have sex based on their likelihood scores 
and actually did) over all predicted positives (i.e., people who were predicted to have sex based 
on their likelihood score. 
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Table 1. 
Demographic characteristics of the sample. 
Variable n % 
Race/Ethnicity 
Black 13 14.1 
Latino 13 14.1 
White 50 54.3 
Multiracial/Other 16 17.4 
Sexual Orientation 
Gay, queer, or homosexual 77 83.7 
Bisexual 15 16.3 
Employment Status 
Full-time 35 38 
Part-time 29 31.5 
Student (unemployed) 9 9.8 
Unemployed 19 20.7 
Highest Educational Attainment 
High school diploma or GED 6 6.5 
Some college or Associate's degree 24 26.1 
Bachelor's or other 4-year degree 40 43.5 
Graduate degree 22 23.9 
Relationship Status 
Single 77 83.7 
Partnered 15 16.3 
Days of Sex Per Week 
Fewer than 3 33 35.9 
3 or More 59 64.1 
M SD 
Age 33.5 11.5 
Note: N = 92. 
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Table 2.  
Hypothetical dosing based on sexual activity in a given week for the ADAPT and IPERGAY dosing schedules. 
Mon Tues Weds Thurs Fri Sat Sun TOTAL 
Sex Event? No No No No No No No 0 Days 
ADAPT - Fixed 1 Fixed -- -- 1 Fixed -- -- -- 2 Doses 
ADAPT - Event-Driven -- -- -- -- -- -- -- 0 Doses 
IPERGAY - Event-Driven -- -- -- -- -- -- -- 0 Doses 
Sex Event? No Yes No No No No No 1 Day 
ADAPT - Fixed 1 Fixed 1 Boost -- 1 Fixed -- -- -- 3 Doses 
ADAPT - Event-Driven 1 Pre 1 Post -- -- -- -- -- 2 Doses 
IPERGAY - Event-Driven -- 2 Pre 1 Post 1 Post -- -- -- 4 Doses 
Sex Event? No Yes Yes No No No No 2 Days 
ADAPT - Fixed 1 Fixed 1 Boost 1 Boost 1 Fixed -- -- -- 4 Doses 
ADAPT - Event-Driven 1 Pre 1 Post 1 Post -- -- -- -- 3 Doses 
IPERGAY - Event-Driven -- 2 Pre 1 Post 1 Post 1 Post -- -- 5 Doses 
Sex Event? No Yes No No Yes No No 2 Days 
ADAPT - Fixed 1 Fixed 1 Boost -- 1 Fixed 1 Boost -- -- 4 Doses 
ADAPT - Event-Driven 1 Pre 1 Post -- 1 Pre 1 Post -- -- 4 Doses 
IPERGAY - Event-Driven -- 2 Pre 1 Post 1 Post 2 Pre 1 Post 1 Post 8 Doses 
E
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